HCC Current Trials
Age – Adult (18-85)
Gender – Female, Male
Disease Type – Hepatocellular carcinoma
Phase – 1b
Length – 60 months
Compensation available.
Inclusion:
– Subjects with confirmed diagnosis of advanced or unresectable or recurrent solid tumor after treatment
– Adequately controlled blood pressure with or without antihypertensive medications
– Males and non-pregnant females
Exclusion:
– HIV positive
– Meningeal carcinomatosis diagnosis
– Previously received E7386 treatment
Eisai: An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Learn More
Additional Information
For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at study@kcresearchinstitute.com.